share_log

Rayont Inc- RAYT- Reports 10-Q for the Three -Month Ending September 30, 2022, Financial Results.

Rayont Inc- RAYT- Reports 10-Q for the Three -Month Ending September 30, 2022, Financial Results.

瑞揚股份有限公司-截至 2022 年 9 月 30 日的三個月財務業績報告 10-Q
GlobeNewswire ·  2023/01/17 22:06

Palo Alto, California, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international personalized natural healthcare company, today reported financial results for the three-month ended September 30, 2022.

加利福尼亞州帕洛阿爾託,2023年1月17日(Global Newswire)--國際個性化自然保健公司Rayont Inc.(“Rayont”or“Company”)(場外交易代碼:RAYT)今天公佈了截至2022年9月30日的三個月的財務業績。

Business Highlights Within the Three-Month ended September 30, 2022:

中的業務亮點THREE-截至月底九月 30, 2022:

Ms. Marshini Moodley, CEO and CFO, said, "We recorded an increase in both the revenue and gross profit for the period ended September 30, 2022 compared to same period last year, mainly due to acquisition of the business of No More Knots Pty Ltd, No More Knots (Newmarket) Pty Ltd, No More Knots (Taringa) Pty Ltd, Ipswich Massage Pty Ltd and Tugun Compounding Pharmacy Pty Ltd.

首席執行官兼首席財務官Marshini Moodley女士表示:“與去年同期相比,我們在截至2022年9月30日止期間的收入和毛利均錄得增長,這主要是由於收購了No More Knots Pty Ltd、No Knots(Newmarket)Pty Ltd、No Knots(Taringa)Pty Ltd、Ipswich Masage Pty Ltd和Tugan Componding Pharmacy Pty Ltd的業務。

Three-month Ending September 30, 2022, Financial Results:

THREE-月末九月 30, 2022,財務業績:

    Three Months Ended September 30,  
    2022     2021  
Revenues   $ 1,368,677     $ 687,523  
Gross Profit   $ 798,262     $ 358,173  
THREE截至的月份九月 30,
2022 2021
收入 $ 1,368,677 $ 687,523
毛利 $ 798,262 $ 358,173

Improved Balance Sheet Results

改善資產負債表業績

      September 30,
2022
      June 30,
2022
 
Cash   $ 28,921     $ 185,782  
Total Assets   $ 8,980,404     $ 14,193,235  
Total Liabilities   $ 2,678,754     $ 9,099,623  
Total Stockholders' Equity   $ 6,301,650     $ 5,093,612  
九月 30,
2022
6月30日,
2022
現金 $ 28,921 $ 185,782
總資產 $ 8,980,404 $ 14,193,235
總負債 $ 2,678,754 $ 9,099,623
股東權益總額 $ 6,301,650 $ 5,093,612

Marshini Moodley added, "Our quarterly performance reflecting decreased total asset portfolio and total liabilities mainly as result of the sale of three subsidiaries of the group that included mostly the land, properties and loans related with those properties. Due to that, the working capital is improved as there was a working capital deficit of $83,884 on June 30, 2022 and working capital of $1,730,581 on September 30, 2022. Our cash reserves have decreased due to capital investments and servicing loan interest received to cover different investments done from the Company during the quarter".

Marshini Moodley補充説:我們的季度業績反映了總資產組合和總負債的減少,這主要是由於出售了集團的三家子公司,其中主要包括土地、物業和與該等物業相關的貸款。因此,營運資本有所改善,因為存在營運資本赤字$83,8842022年6月30日和營運資金$1,730,5812022年9月30日。我們的現金儲備有所減少,原因是資本投資和為支付公司在本季度進行的不同投資而收到的還本付息貸款“。

Strategies for Growth

增長戰略

During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:

在本財政年度,我們繼續開展旨在改善Rayont Inc.整體業績的幾項關鍵活動,即:

  • Continue to consolidate the operations of Prema Life with that of Tugun Compounding Pharmacy to drive cost reduction and efficiencies across both operations.
  • Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
  • Continue with smaller acquisitions that can contribute to revenue growth and synergies across the group. We expect that the acquisitions made to date will contribute to significant revenue and profit growth this financial year.
  • 繼續整合普萊瑪人壽和圖貢複方藥房的業務,以推動兩項業務的成本降低和效率提高。
  • 為全球主要市場澳大利亞和美國推出面向自然療法的Health腳本遠程健康平臺。
  • 繼續進行規模較小的收購,以促進整個集團的收入增長和協同效應。我們預計,到目前為止進行的收購將為本財年的收入和利潤增長做出重大貢獻。

These activities are being worked on and we will communicate their completions as we achieve them.

這些活動正在進行中,我們將在實現它們時通報它們的完成情況。

Disclosure Regarding the Financial Reports Provided in the Form 10-Q

披露R關注美國的F財務狀況R報告前提是在表格10-Q中

The auditor's review for current version of the Form 10Q has not been completed due to the fact that the valuation report for the acquisition of the business of Ipswich Massage Pty Ltd, Prema Life Pty Ltd and Tugun Compounding Pharmacy Pty Ltd by an independent expert that not been completed. The company is in process of procuring these reports.

核數師對當前版本的表格10Q的審核尚未完成,原因是獨立專家收購Ipswich按摩器有限公司、Prema Life Pty有限公司和Tugan Componding Pharmacy Pty Ltd的業務的估值報告尚未完成。該公司正在採購這些報告。

Once the auditor's review is ready, the Company will file an amendment to its Form 10-Q.

一旦審計師的審查準備就緒,公司將提交對其10-Q表格的修正。

About Rayont Inc.

A回合賽人造絲Inc.

Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on personalized natural healthcare industry.

Rayont,Inc.(RAYT)是一家上市公司,自2011年成立以來一直在美國內華達州成立。2018年,公司重新定位,專注於個性化的自然保健行業。

Rayont uses scientific tools such as DNA, microbiome, iridology and other tests to personalize diagnoses, prescription and treatments of natural complementary and alternative medicine products, services and treatments to our patients in the markets we operate.

Rayont使用DNA、微生物組、虹膜學和其他測試等科學工具,為我們運營的市場中的患者提供個性化的天然補充和替代醫學產品、服務和治療的診斷、處方和治療。

For further information, please visit 

如需進一步資料,請瀏覽

SAFE HARBOR

安全港

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

本新聞稿中的某些陳述可能包含1933年《證券法》第175條規定的前瞻性信息,受1934年《證券交易法》第3b-6條的約束,並受這些規定所創造的安全港的約束。本新聞稿中包含的除事實陳述外的所有陳述,包括但不限於有關公司潛在的未來計劃和目標的陳述,均為前瞻性陳述,涉及風險和不確定性。不能保證這樣的陳述將被證明是準確的,其他結果和進一步的事件可能與這種陳述中預期的大不相同。未來的事件和實際結果可能與前瞻性陳述中陳述的、預期的或潛在的大不相同。

Company Contact:
Investor Relations
ir@rayont.com

公司聯繫人:
投資者關係
郵箱:ir@rayont.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論